Macular degeneration
This article was originally published in The Gray Sheet
Executive Summary
Medicare Coverage Advisory Committee will convene Sept. 9 to review the current national non-coverage policy for ocular photodynamic therapy with verteporfin for age-related macular degeneration patients with occult and no classic subfoveal choroidal neovascularization as determined by a fluorescein angiogram. 1CMS review of the policy was announced July 25, pursuant to a May 27 settlement CMS reached with the American Council for the Blind and American Association of People with Disabilities in Washington, D.C. federal court (2"The Gray Sheet" June 2, 2003, p. 7). The suit was filed against CMS in August 2002...
You may also be interested in...
Medicare Appeals Rule Expedited By Visudyne Settlement; MCAC To Convene
CMS' Medicare Coverage Advisory Committee will review initial data from QLT, Inc.'s Phase III trial investigating Visudyne (verteporfin) ocular photodynamic therapy in age-related macular degeneration patients with occult lesions
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.